Pfizer reported better-than-expected quarterly profits on Tuesday behind cost cuts and growth in some non-Covid-related products including the blood clot drug Eliquis.

Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company ...

After doctor’s office visits for flu dipped early this year, they jumped past the previous season peak at the end of last ...

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

Bose, 54, promised a junior colleague more money for a 'couple of hours' work than he would make in a month if she went along ...

A Georgia sculptor gave birth during the coronavirus pandemic. Five years later, she is designing a monument honoring those who have died with COVID-19.

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

2025年2月4日（周二），全球知名制药巨头辉瑞公司（Pfizer，股票代码PFE）公布了2024年第四季度及全年的财务业绩，收入和调整后盈利均超出了华尔街分析师的普遍预期。辉瑞报告调整后每股收益为0.63美元，远高于分析师预期的0.47美元，同时收 ...